Mouth Ulcer Treatment Market Report Scope & Overview:

The Mouth Ulcer Treatment Market was valued at USD 1.80 Billion in 2025 and is expected to reach USD 2.50 Billion by 2035, growing at a CAGR of 3.34% from 2026–2035.

The market for mouth ulcer treatments has been experiencing steady growth in conjunction with the prevalence of oral disorders such as aphthous stomatitis, oral lichen planus, and oral candidiasis. Increased consumer awareness regarding their oral health, the need for over-the-counter treatment options, and improved availability of healthcare in developing nations have been aiding this market's growth. As per the World Health Organization, oral diseases affect around 3.7 billion individuals worldwide; this is a major and largely avoidable public health burden that exists at all ages. Ongoing product development activities and a growing elderly population, a demographic group vulnerable to mouth ulcers, are driving this market's growth.

As stated by the World Health Organization, the rate of serious oral illnesses has continued to increase worldwide due to increased urbanization and altered lifestyle practices. This has been driven by the lack of fluoride in drinking water sources and toothpaste, and at the same time the availability of affordable and high-sugar diets.

Market Size and Forecast

• Market Size in 2026E: USD 1.86 Billion

• Market Size by 2035: USD 2.50 Billion

• CAGR: 3.34% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

To Get More Information On Mouth Ulcer Treatment Market - Request Free Sample Report

Mouth Ulcer Treatment Market Trends

• Growing awareness of the microbial origins of certain mouth ulcers is driving demand for targeted antimicrobial therapies that address both symptom relief and underlying infection.

• Gel-based formulations remain the preferred drug form owing to their extended mucosal contact time, though spray formulations are gaining traction for their convenient, contact-free application.

• Online pharmacy channels are expanding rapidly for oral care products, supported by growing e-commerce infrastructure and consumer preference for convenient, discreet purchasing options.

• Rising diagnosis rates for oral candidiasis among immunosuppressed patients and denture users are broadening the indication base for antifungal-inclusive treatment formulations.

• Combination therapies addressing both pain relief and underlying microbial or inflammatory causes are gaining physician and consumer preference over single-mechanism treatments.

U.S. Mouth Ulcer Treatment Market Outlook

The U.S. Mouth Ulcer Treatment Market was valued at approximately USD 0.59 Billion in 2025 and is expected to reach approximately USD 0.83 Billion by 2035, growing at a CAGR of approximately 3.50%.

The United States leads the North American mouth ulcer treatment market, supported by high healthcare spending, extensive availability of over-the-counter oral care products, and strong consumer awareness of oral health management. The presence of major pharmaceutical and oral care companies operating domestically further consolidates the country's dominant regional position, supported by well-established retail pharmacy distribution networks that provide broad consumer access to gels, mouthwashes, and lozenges.

In October 2023, Pfizer Inc. reported that the U.S. Food and Drug Administration approved VELSIPITY (etrasimod), an oral once-daily selective sphingosine-1-phosphate receptor modulator, for the treatment of moderately to severely active adult ulcerative colitis. While targeted primarily at inflammatory bowel disease, the approval reflects continued regulatory momentum for oral formulation therapeutics addressing chronic inflammatory conditions with mucosal involvement.

Mouth Ulcer Treatment Market Segment Analysis

• By Drug Class, the Analgesics & Corticosteroids segment dominated the Mouth Ulcer Treatment Market with a 36.15% revenue share in 2025, while the Antimicrobial segment is the fastest growing.

• By Drug Form, the Gels segment dominated the Mouth Ulcer Treatment Market with a 42.10% revenue share in 2025, while the Sprays segment is the fastest growing.

• By Indication, the Aphthous Stomatitis segment dominated the Mouth Ulcer Treatment Market with a 54.11% revenue share in 2025, while the Oral Candidiasis segment is the fastest growing.

• By Distribution Channel, the Retail Pharmacies segment dominated the Mouth Ulcer Treatment Market with a 46.14% revenue share in 2025, while the Online Pharmacies segment is the fastest growing.

By Drug Class, analgesics and corticosteroids dominate, antimicrobial treatments register the fastest growth

Analgesics and corticosteroids accounted for the largest drug class share in 2025, at 36.15%, owing to their high efficacy in reducing pain and inflammation, the key symptoms associated with mouth ulcers. These medications provide rapid symptomatic relief and are the preferred choice among both healthcare providers and patients, widely available in gel and cream formulations for moderate to severe cases.

Antimicrobial treatments are projected to register the fastest growth over the forecast period, driven by increasing awareness of the bacterial and fungal infection component in provoking or exacerbating mouth ulcers. Growing availability of antimicrobial mouthwashes and lozenges, combined with rising prescription of combination therapies addressing both symptoms and underlying microbial causes, continues to support accelerated adoption of this drug class.

By Drug Form, gels lead the market, sprays register the fastest growth

In 2025, gels had the highest market share in terms of drug forms owing to their better applicability and longer mucosal contact time. Gel-based drugs ensure that the active ingredients, such as corticosteroids and analgesics, come into continuous contact with the damaged surface through targeted administration, thereby improving the efficacy of the therapy and offering rapid relief from pain.

Among all drug forms, sprays are likely to have the highest growth rate because of rising consumer preference for more hygienic treatment methods. This is mainly due to the fast and non-contact applicability offered by the drugs, which makes them especially useful for children and people suffering from severe oral pain.

By Indication, aphthous stomatitis leads the market, oral candidiasis registers the fastest growth

Aphthous stomatitis dominated the indication-wise market share with 54.11% share in 2025 on account of high prevalence rates and recurrence nature of this condition. According to published studies, around 25% of the world population suffers from Recurrent Aphthous Stomatitis which ranks it amongst the commonly occurring mucosal conditions in the world, especially among young adults and adolescents.

Oral candidiasis is expected to grow the fastest among the indication segments owing to the growing incidence rates of immunocompromised diseases, increasing use of antibiotics and aging population suffering from dental prosthesis. Growing sensitivity of diagnosis for fungal infections and development of antifungal treatment options are likely to drive its rapid growth.

By Distribution Channel, retail pharmacies dominate, online pharmacies register the fastest growth

Retail pharmacies have been identified as the most dominating segment within the distribution channel, representing 46.14% of total sales in 2025 due to high availability, fast accessibility of products, and consumers' preferences for consultations with a pharmacist. Retail pharmacies have their network all over cities and towns, allowing easy accessibility to gels, mouthwashes, and lozenges without prescription.

The online pharmacies are estimated to experience the fastest growth rate during the forecast period due to increased penetration of internet technologies, higher convenience preferences of consumers, and development of the e-commerce sector. Consumers are increasingly preferring online purchases due to home delivery and the ability to compare prices among other benefits.

Regional Analysis

North America Mouth Ulcer Treatment Market Insights

North America dominated the mouth ulcer treatment market in 2025, with a 38.21% share, supported by well-established healthcare facilities, high oral health awareness, and elevated incidence of lifestyle risk factors including stress and nutritional deficiency. The region benefits from strong distribution channels, broad availability of over-the-counter medications, and a well-established pharmaceutical industry.

Higher healthcare expenditure and the presence of major market participants continue to support early diagnosis and timely management of mouth ulcers, reinforcing the region's market leadership. The United States accounts for the substantial majority of regional revenue, while Canada contributes a smaller but consistent share of demand.

Get Customized Report as Per Your Business Requirement - Enquiry Now

Asia Pacific Mouth Ulcer Treatment Market Insights

Asia Pacific is the fastest-growing regional market, with a projected CAGR of 4.65% through the forecast period, driven by a large and aging population, high incidence of oral disease, and increasing healthcare access across emerging economies. Rising consumer awareness, ongoing urbanization, and evolving dietary habits continue to drive demand for mouth ulcer treatment products throughout the region.

Government initiatives aimed at strengthening healthcare infrastructure, alongside the rapid expansion of retail and e-commerce pharmacy channels, continue to support regional market growth. China, India, and Japan represent the region's principal growth markets.

Europe Mouth Ulcer Treatment Market Insights

Germany is a leader in the European region for mouth ulcers treatment due to an extensive health care sector, high awareness regarding oral health, and established presence of companies in the health care sector and pharmacy sector. The country enjoys a high prevalence of over-the-counter drug usage and availability of advanced treatment procedures.

The country will continue to be a leader in the region due to its emphasis on preventive care and regular visits to the dentist. Some of the notable secondary markets in the region include the United Kingdom, France, and Italy.

MEA & Latin America Mouth Ulcer Treatment Market Insights

Latin America and the Middle East and Africa are exhibiting moderate growth in mouth ulcer treatment adoption, supported by improving healthcare accessibility and growing awareness of oral hygiene. Economic limitations and comparatively lower healthcare expenditure may restrain the pace of growth in certain markets, though ongoing urbanization continues to support gradual expansion.

Rising demand for over-the-counter oral care products continues to drive market activity across both regions, with Saudi Arabia and Brazil representing the leading national markets within their respective regions. Continued investment in healthcare infrastructure is expected to support steady, incremental growth throughout the forecast period.

Market Dynamics

Growth Drivers: Increasing incidence of oral disorders sustains treatment demand

The increased frequency of diseases such as aphthous stomatitis, oral candidiasis, and oral lichen planus is a major factor leading to growth in the mouth ulcers treatment market. Such diseases are triggered due to stress, hormonal changes, nutritional problems like lack of vitamins B12, C, and folic acid, food allergies, and poor oral hygiene practices, with tobacco and alcohol use further adding to the stress of oral tissues and increased ulcer formations.

According to the World Health Organization, the incidence of oral diseases across the globe is increasing due to factors such as urbanization, changes in dietary habits, and lack of fluoride and oral health care among others. As more people suffer from such ailments, demand for fast acting treatments will continue to support market growth.

Restraints: Limited awareness in developing regions constrains market growth

In spite of the presence of effective treatments, a significant portion of the population in low and middle income countries lacks knowledge about how to practice good oral hygiene and existing methods of treatment for mouth ulcers. Lack of knowledge causes lack of diagnosis and treatment, especially in rural areas and among the underprivileged masses.

Stigma attached to culture and limited availability of dentists or doctors also contributes towards hampering the market growth, as most people prefer home-based remedies instead of medically approved treatments.

Opportunities: Product innovation and expanding elderly population create growth potential

The increasing number of elderly people worldwide is an important demographic that can be treated for mouth ulcers due to their physiological vulnerability as a result of old age, usage of dentures, and polypharmacy. The elderly usually have cases of dry mouth and inflamed mucosa, which makes them more vulnerable to mouth ulcers.

There is considerable potential in terms of pharmaceutical innovation in terms of creating medicines that will provide not only symptomatic relief but also address the problem at its root. There are plenty of opportunities for pharmaceutical companies that have distribution channels all around the world.

Recent Developments:

• 2023: In October 2023, Pfizer Inc. reported FDA approval of VELSIPITY (etrasimod), an oral once-daily selective S1P receptor modulator, for the treatment of moderately to severely active adult ulcerative colitis.

• 2024: In March 2024, Bausch Health Companies Inc. and its gastroenterology unit, Salix Pharmaceuticals, publicly endorsed a Phase 2 investigator-initiated study assessing RELISTOR in patients with resectable head and neck squamous cell carcinoma.

• 2024: Church & Dwight Co., Inc. continued expanding its oral care product portfolio throughout 2024, including formulation updates to its ulcer and denture-relief product lines under established consumer oral care brands.

Mouth Ulcer Treatment Market Key Players

• GlaxoSmithKline plc

• Pfizer Inc.

• Colgate-Palmolive Company

• 3M Company

• Bristol Myers Squibb Company

• Sun Pharmaceutical Industries Ltd.

• Bausch Health Companies Inc.

• Church & Dwight Co., Inc.

• Blistex Inc.

• ECR Pharmaceuticals

• Johnson & Johnson Services, Inc.

• Reckitt Benckiser Group plc

• Procter & Gamble Co.

• Sanofi S.A.

• Perrigo Company plc

• Cadila Pharmaceuticals Ltd.

• Dr. Reddy's Laboratories

• Cipla Limited

• Lupin Limited

• Haleon plc

Mouth Ulcer Treatment Market Report Scope: